Sellas Life Sciences Group Inc
NASDAQ:SLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sellas Life Sciences Group Inc
Net Issuance of Common Stock
Sellas Life Sciences Group Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sellas Life Sciences Group Inc
NASDAQ:SLS
|
Net Issuance of Common Stock
$86.8m
|
CAGR 3-Years
54%
|
CAGR 5-Years
18%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$808m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$1.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
17%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$2.8B
|
CAGR 3-Years
-71%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Sellas Life Sciences Group Inc
Glance View
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
See Also
What is Sellas Life Sciences Group Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
86.8m
USD
Based on the financial report for Dec 31, 2025, Sellas Life Sciences Group Inc's Net Issuance of Common Stock amounts to 86.8m USD.
What is Sellas Life Sciences Group Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
6%
Over the last year, the Net Issuance of Common Stock growth was 85%. The average annual Net Issuance of Common Stock growth rates for Sellas Life Sciences Group Inc have been 54% over the past three years , 18% over the past five years , and 6% over the past ten years .
